ArticleCardiovascular diabetology2026
Hepatic metabolic burden and all-cause mortality across glucose metabolism statuses in a cardiovascular-kidney-metabolic syndrome population: insights from the National Health and Nutrition Examination Survey (NHANES).
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic disorder-MASLD-cardiovascular disease-kidney disease (MMCK) syndrome: an expansion of the Cardiovascular-Kidney-Metabolic (CKM) framework.Cardiovascular diabetology. Endocrinology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundHepatic metabolic burden is an integral component of cardiometabolic risk. However, the association of hepatic metabolic burden assessed by the fatty liver index (FLI) with all-cause mortality in cardiovascular-kidney-metabolic (CKM) syndrome has not been well described when individuals are stratified by glucose metabolism status. Therefore, this study aimed to evaluate the association between FLI and all-cause mortality across different glucose metabolism states in adults with CKM syndrome.
methodsData were derived from the National Health and Nutrition Examination Survey (NHANES) 1999-2018. Adults with CKM syndrome according to the AHA/ADA framework were included and categorized by glucose metabolism status as normoglycemia, prediabetes, or diabetes. Hepatic metabolic burden was assessed using FLI. Weighted multivariable Cox proportional hazards models and restricted cubic spline (RCS) analyses were applied to examine the associations between FLI and all-cause mortality across glucose metabolism status. Additionally, joint analyses with combined FLI (FLI ≥ 60 vs. <60) and glycemic categories and multiple sensitivity analyses were performed.
resultsAmong 19,107 participants with CKM syndrome (weighted N = 105,007,226), 2482 deaths occurred over a median follow-up of 9.42 years. No robust independent association was observed between FLI and all-cause mortality among individuals with normoglycemia or prediabetes after multivariable adjustment. In contrast, among individuals with diabetes, multivariable Cox regression and RCS analysis indicated that higher FLI was significantly associated with increased mortality risk and demonstrated a J-shaped nonlinear dose-response relationship. Joint analyses further showed that elevated FLI was associated with progressively higher death risk in the presence of impaired glucose metabolism, with the highest risk observed among individuals with diabetes and FLI ≥ 60. Multiple sensitivity analyses confirmed that the main analysis results were robust.
conclusionsWithin the CKM syndrome spectrum, elevated FLI was associated with a higher risk of all-cause mortality among individuals with diabetes, with a J-shaped association, whereas the association between FLI and all-cause mortality was not significant among individuals with normoglycemia or prediabetes. These findings suggest that the relationship between FLI and mortality in CKM populations may vary according to glycemic status and highlight the importance of considering glycemic context when interpreting liver-related metabolic markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.